While there have been advancements in standard care for IBD patients over the years, current treatments with antibiotics (ciprofloxacin, metronidazole), aminosalicylates (5-ASAs), corticosteroids (prednisone, hydrocortisone, budesonide), immunomodulators (azathioprine, cyclosporine, methotrexate), and biologics (anti-TNF, anti-integrins) all have potential negative side-effects associated with them, in addition to non-responding patients in some cases. This evidence concerns the gene TNF and inflammatory bowel disease.